Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update
Lifecore Biomedical reported Q2 revenue of $34.2 million, down 6.2% year-over-year, with a net loss of $6.2 million or $0.19 per share. Despite the revenue decline, the company reaffirmed its full-year 2026 guidance for revenue of $120-$125 million and Adjusted EBITDA of $20.5-$25 million.
Key figures
- Revenue
- 34200000
- Guidance
- 2026 revenue $120M-$125M; Adjusted EBITDA $20.5M-$25M
- Revenue Yoy
- -6.2%
- Liquidity
- 38800000
- Gross profit
- 12100000
- Adjusted ebitda
- 8600000
- Operating income
- 2567000
- Late stage programs
- 8
- Programs added 12mo
- 13
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.